GlassScriptPhysician profile
George Chase
NPI 1396220083
$102,229.54
in general payments reported to CMS, 2019-2025
14 companies · $366 in 2025
The $366 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $537 · 2024: $101K · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $96K · Food and Beverage: $5,472 · Travel and Lodging: $1,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $95,666.68 |
| Food and Beverage | $5,472.19 |
| Travel and Lodging | $1,090.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $96,793.47 | 2024 | Proclaim, Eterna, Axium |
| Boston Scientific Corporation | $2,219.20 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $576.95 | 2024-2025 | Intellis Adaptivestim, Inceptiv |
| Saluda Medical Americas, INC. | $551.52 | 2024 | Evoke |
| Abbvie INC. | $441.56 | 2023-2024 | |
| Nevro Corp. | $308.36 | 2024 | Senza |
| Globus Medical, INC. | $259.99 | 2025 | Senza |
| Teva Pharmaceuticals USA, INC. | $249.23 | 2024 | Ajovy, Austedo Xr |
| Painteq LLC | $189.56 | 2024 | Painteq |
| Averitas Pharma INC. | $150.06 | 2024 | Qutenza |
| Biotronik Nro, INC. | $147.07 | 2024 | Prospera |
| Vertos Medical, INC. | $143.44 | 2024 | Mild Device Kit |
| Lundbeck LLC | $108.53 | 2023 | Vyepti |
| Curonix LLC | $90.60 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Chase listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.